Analysts say Dexcom’s FDA warning unlikely to impact 2025 revenue
Dexcom is still expected to hit 2025 revenue despite the diabetes device giant receiving a warning from the US Food…
Diabetes Care Devices
-
-
Glucotrack hits trial success for direct blood measuring CGM
Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures glucose levels from a…
-
Beta Bionics raises $204m to kickstart medtech IPO season
Beta Bionics has begun life as a public company with a $204m initial public offering (IPO), significantly higher than its…
-
Beta Bionics joins IPO uptick, aims to raise $114.4m in Nasdaq listing
Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics…
-
How Dexcom and ŌURA are unifying two distinct market sectors
Technology has come a long way since the first blood glucose meter was developed by Anton H Clemens in 1965.…
-
JP Morgan 2025: Dexcom shares up 5% after 2025 outlook forecasts $4.6bn in revenue
Dexcom has shaken off the lower sales outlook that plagued its share price in 2024 as the diabetes device developer…
-
Dexcom implements GenAI into glucose biosensor devices
The applications of generative artificial intelligence (GenAI) have reached continuous glucose monitoring after DexCom launched rolled out the technology into…
-
Insulet adds Abbott’s FreeStyle Libre 2 Plus to Omnipod 5’s compatibility roster
Diabetes patients in the US will have greater flexibility in managing insulin delivery after Insulet announced its Omnipod pump is…
-
Medtronic’s insulin pen app gains FDA clearance
Medtronic has received clearance from the US Food and Drug Administration (FDA) for its new InPen app, paving the way…
-
Dexcom invests $75m in ŌURA to forge partnership
Diabetes care device developer Dexcom and ŌURA, maker of the Oura smart ring, have announced a strategic partnership that aim…
